We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Lab rats

25 January 2021 By Aimee Donnellan

AstraZeneca’s $39 bln takeover of Alexion highlights the growing influence of pushy shareholders such as Elliott in healthcare. Drugmakers are tricky targets, but waste and inefficient markets create opportunities. Medical technology groups, like Fresenius, could be next.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)